“We set out in 2016 to become the leading precision oncology company focused on synthetic lethality in genomic instability and DNA damage repair, and have since built a strong pipeline of product candidates based upon our proprietary genome-wide, CRISPR enabled SNIPRx platform,” said
Operational Highlights:
-
Initiated a phase 1/2 clinical trial evaluating
RP-3500 as a monotherapy and in combination with Pfizer's PARPi, talazoparib. InJuly 2020 , the Company received acceptance from theU.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application and commenced dosing for the first patient in the Phase 1/2 clinical trial ofRP-3500 .
-
Completed initial public offering (IPO). In
June 2020 , Repare closed an upsized IPO of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering price of$20.00 per share. The net proceeds to Repare, after deducting underwriting commissions and offering expenses, were$232 million .
-
Bristol Myers Squibb collaboration. In
May 2020 , Repare entered into an exclusive, worldwide target discovery collaboration with Bristol Myers Squibb. Repare received an upfront payment from Bristol Myers Squibb of$65 million in Q2 2020, which included a$15 million equity investment in Repare in the form of a warrant that automatically exercised into 750,000 common shares at the public offering price of$20.00 per share upon IPO. In addition, Repare will be eligible to receive additional contingent payments of up to approximately$3 billion in the form of license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by Bristol Myers Squibb.
-
Appointed new director. In
June 2020 , Repare appointedAnn D. Rhoads to its Board of Directors and as Chairperson of its Audit Committee.
Second Quarter 2020 Financial Results:
-
Cash and restricted cash: Cash and restricted cash as of
June 30, 2020 were$370.1 million .
-
Research and development expenses, net of tax credits (Net R&D): Net R&D expenses were
$9.0 million and$17.6 million for the three and six month periods endedJune 30, 2020 , respectively, as compared to$4.9 million and$8.6 million in the same periods in the prior year, respectively. Increases in R&D for the three and six month periods endedJune 30, 2020 were primarily due to increases in development costs related to Repare’sRP-3500 and CCNE1-SL programs, as well as increases in personnel related expenses and certain other R&D expenses.
-
General and administrative (G&A) expenses: G&A expenses were
$3.4 million and$5.4 million for the three and six month periods endedJune 30, 2020 , respectively, as compared to$1 million and$2.1 million in the same periods in the prior year, respectively. Increases in G&A for the three and six month periods endedJune 30, 2020 were due to increases in payroll and personnel costs as well as increases in legal, professional and D&O insurance costs, which in turn increased as a result of our recent IPO.
-
Net loss: Net loss was
$11.8 million , or$2.45 per share in the second quarter of 2020 and$24.4 million , or$7.56 per share, in the first half of 2020.
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those patients most likely to achieve clinical benefit from resulting product candidates.
About
SNIPRx® is a registered trademark of
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s collaboration with Bristol Myers Squibb; the discovery of potential product candidates using SNIPRx® platform; and the clinical development of the Company’s pipeline and its research and development programs. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company’s final prospectus dated
|
Condensed Consolidated Balance Sheets (Unaudited)
(Amounts in thousands of |
||||||||
|
|
|
As of
|
|
As of
|
||||
|
|
|
2020 |
|
2019 |
||||
|
ASSETS |
|
|
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
369,933 |
|
|
$ |
94,797 |
|
|
Research and development tax credits receivable |
|
|
1,414 |
|
|
|
1,080 |
|
|
Other receivables |
|
|
2,621 |
|
|
|
1,976 |
|
|
Prepaid expenses and other current assets |
|
|
3,296 |
|
|
|
719 |
|
|
Total current assets |
|
|
377,264 |
|
|
|
98,572 |
|
|
Property and equipment, net |
|
|
2,453 |
|
|
|
2,390 |
|
|
Restricted cash |
|
|
199 |
|
|
|
208 |
|
|
Operating lease right-of-use assets |
|
|
729 |
|
|
|
1,034 |
|
|
Other assets |
|
|
894 |
|
|
|
359 |
|
|
Deferred tax assets |
|
|
192 |
|
|
|
132 |
|
|
TOTAL ASSETS |
|
$ |
381,731 |
|
|
$ |
102,695 |
|
|
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
3,576 |
|
|
$ |
2,127 |
|
|
Accrued expenses and other current liabilities |
|
|
5,262 |
|
|
|
1,276 |
|
|
Operating lease liability, current portion |
|
|
608 |
|
|
|
625 |
|
|
Income tax payable |
|
|
351 |
|
|
|
218 |
|
|
Total current liabilities |
|
|
9,797 |
|
|
|
4,246 |
|
|
Operating lease liability, net of current portion |
|
|
136 |
|
|
|
439 |
|
|
Deferred revenue |
|
|
58,142 |
|
|
|
8,142 |
|
|
TOTAL LIABILITIES |
|
|
68,075 |
|
|
|
12,827 |
|
|
Series A convertible preferred shares, no par value per share; 0 shares and unlimited shares authorized as of |
|
|
— |
|
|
|
53,749 |
|
|
Series B convertible preferred shares, no par value per share; 0 shares and unlimited shares authorized as of |
|
|
— |
|
|
|
82,248 |
|
|
TOTAL CONVERTIBLE PREFERRED SHARES |
|
|
— |
|
|
|
135,997 |
|
|
SHAREHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
|
Preferred shares, no par value per share; unlimited shares and 0 shares authorized as of |
|
|
— |
|
|
|
— |
|
|
Common shares, no par value per share; unlimited shares authorized as of |
|
|
383,818 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
|
4,182 |
|
|
|
3,811 |
|
|
Accumulated deficit |
|
|
(74,344 |
) |
|
|
(49,941 |
) |
|
Total shareholders’ equity (deficit) |
|
|
313,656 |
|
|
|
(46,129 |
) |
|
TOTAL LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (DEFICIT) |
|
$ |
381,731 |
|
|
$ |
102,695 |
|
|
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Amounts in thousands of |
||||||||||||||||
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development, net of tax credits |
|
$ |
8,951 |
|
|
$ |
4,853 |
|
|
$ |
17,583 |
|
|
$ |
8,556 |
|
|
General and administrative |
|
|
3,372 |
|
|
|
1,032 |
|
|
|
5,555 |
|
|
|
2,108 |
|
|
Total operating expenses |
|
|
12,323 |
|
|
|
5,885 |
|
|
|
23,138 |
|
|
|
10,664 |
|
|
Loss from operations |
|
|
(12,323 |
) |
|
|
(5,885 |
) |
|
|
(23,138 |
) |
|
|
(10,664 |
) |
|
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized and unrealized gain (loss) on foreign exchange |
|
|
595 |
|
|
|
227 |
|
|
|
(1,136 |
) |
|
|
299 |
|
|
Change in fair value of Series A preferred share tranche obligation |
|
|
— |
|
|
|
(680 |
) |
|
|
— |
|
|
|
(700 |
) |
|
Other expense |
|
|
(4 |
) |
|
|
(1 |
) |
|
|
(6 |
) |
|
|
(3 |
) |
|
Total other income (expense), net |
|
|
591 |
|
|
|
(454 |
) |
|
|
(1,142 |
) |
|
|
(404 |
) |
|
Loss before income taxes |
|
|
(11,732 |
) |
|
|
(6,339 |
) |
|
|
(24,280 |
) |
|
|
(11,068 |
) |
|
Income tax expense |
|
|
(70 |
) |
|
|
(20 |
) |
|
|
(123 |
) |
|
|
(129 |
) |
|
Net loss and comprehensive loss |
|
$ |
(11,802 |
) |
|
$ |
(6,359 |
) |
|
$ |
(24,403 |
) |
|
$ |
(11,197 |
) |
|
Net loss attributable to common shareholders—basic and diluted |
|
$ |
(11,802 |
) |
|
$ |
(6,359 |
) |
|
$ |
(24,403 |
) |
|
$ |
(11,197 |
) |
|
Net loss per share attributable to common shareholders—basic and diluted |
|
$ |
(2.45 |
) |
|
$ |
(4.16 |
) |
|
$ |
(7.56 |
) |
|
$ |
(7.33 |
) |
|
Weighted-average common shares outstanding—basic and diluted |
|
|
4,825,214 |
|
|
|
1,528,374 |
|
|
|
3,229,635 |
|
|
|
1,528,374 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Amounts in thousands of |
||||||||
|
|
|
Six Months Ended
|
||||||
|
|
|
2020 |
|
2019 |
||||
|
Cash Flows From Operating Activities: |
|
|
|
|
|
|
|
|
|
Net loss and comprehensive loss for the period |
|
$ |
(24,403 |
) |
|
$ |
(11,197 |
) |
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
|
Share-based compensation expense |
|
|
660 |
|
|
|
186 |
|
|
Depreciation expense |
|
|
403 |
|
|
|
262 |
|
|
Change in fair value of the Series A preferred shares tranche obligation |
|
|
— |
|
|
|
700 |
|
|
Non-cash lease expense |
|
|
305 |
|
|
|
86 |
|
|
Foreign exchange loss (gain) |
|
|
1,162 |
|
|
|
(522 |
) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
(2,577 |
) |
|
|
(155 |
) |
|
Research and development tax credits receivable |
|
|
(381 |
) |
|
|
(246 |
) |
|
Other receivables |
|
|
(725 |
) |
|
|
(566 |
) |
|
Deferred tax asset |
|
|
(60 |
) |
|
|
(42 |
) |
|
Other non-current assets |
|
|
(535 |
) |
|
|
(15 |
) |
|
Accounts payable |
|
|
915 |
|
|
|
260 |
|
|
Accrued expenses and other current liabilities |
|
|
2,371 |
|
|
|
(119 |
) |
|
Operating lease liability, current portion |
|
|
(9 |
) |
|
|
15 |
|
|
Income tax payable |
|
|
133 |
|
|
|
72 |
|
|
Operating lease liability, net of current portion |
|
|
(292 |
) |
|
|
(93 |
) |
|
Deferred revenue |
|
|
50,000 |
|
|
|
8,142 |
|
|
Net cash provided by (used in) operating activities |
|
|
26,967 |
|
|
|
(3,232 |
) |
|
Cash Flows From Investing Activities: |
|
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(43 |
) |
|
|
(380 |
) |
|
Net cash used in investing activities |
|
|
(43 |
) |
|
|
(380 |
) |
|
Cash Flows From Financing Activities: |
|
|
|
|
|
|
|
|
|
Proceeds from issuance of Series A preferred shares, net |
|
|
— |
|
|
|
20,995 |
|
|
Proceeds from exercise of stock options |
|
|
488 |
|
|
|
— |
|
|
Proceeds from issuance of warrant |
|
|
15,000 |
|
|
|
— |
|
|
Net proceeds from issuance of common shares in initial public offering |
|
|
233,760 |
|
|
|
— |
|
|
Net cash provided by financing activities |
|
|
249,248 |
|
|
|
20,995 |
|
|
Effect of exchange rate fluctuations on cash held |
|
|
(1,045 |
) |
|
|
482 |
|
|
Net Increase In Cash And Restricted Cash |
|
|
275,127 |
|
|
|
17,865 |
|
|
Cash and restricted cash at beginning of period |
|
|
95,005 |
|
|
|
10,929 |
|
|
Cash and restricted cash at end of period |
|
$ |
370,132 |
|
|
$ |
28,794 |
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation Of Cash And Restricted Cash |
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
369,933 |
|
|
$ |
28,588 |
|
|
Restricted cash |
|
|
199 |
|
|
|
206 |
|
|
Total cash and restricted cash |
|
$ |
370,132 |
|
|
$ |
28,794 |
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosure Of Cash Flow Information: |
|
|
|
|
|
|
|
|
|
Property and equipment purchases in accounts payable |
|
$ |
423 |
|
|
$ |
14 |
|
|
Initial public offering costs in accounts payable |
|
$ |
102 |
|
|
|
|
|
|
Initial public offering costs in accruals and other current liabilities |
|
$ |
1,615 |
|
|
$ |
— |
|
|
Conversion of Series A and B convertible preferred shares into common shares |
|
$ |
135,997 |
|
|
$ |
— |
|
|
Conversion of warrant into common shares |
|
$ |
15,000 |
|
|
$ |
— |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005641/en/
Repare Contact:
Chief Financial Officer
[email protected]
Investors:
[email protected]
Media:
[email protected]
212-600-1902
Source: